JP2023531008A5 - - Google Patents

Info

Publication number
JP2023531008A5
JP2023531008A5 JP2022578713A JP2022578713A JP2023531008A5 JP 2023531008 A5 JP2023531008 A5 JP 2023531008A5 JP 2022578713 A JP2022578713 A JP 2022578713A JP 2022578713 A JP2022578713 A JP 2022578713A JP 2023531008 A5 JP2023531008 A5 JP 2023531008A5
Authority
JP
Japan
Prior art keywords
disease
disorder
abnormality
pharmaceutically acceptable
pharmaceutical product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022578713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531008A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/066695 external-priority patent/WO2021255279A1/en
Publication of JP2023531008A publication Critical patent/JP2023531008A/ja
Publication of JP2023531008A5 publication Critical patent/JP2023531008A5/ja
Pending legal-status Critical Current

Links

JP2022578713A 2020-06-19 2021-06-18 Nlrp3インフラマソーム経路を調節するジヒドロオキサゾール及びチオ尿素または尿素誘導体 Pending JP2023531008A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20181221.1 2020-06-19
EP20181221 2020-06-19
EP21164097 2021-03-22
EP21164097.4 2021-03-22
PCT/EP2021/066695 WO2021255279A1 (en) 2020-06-19 2021-06-18 D i h yd rooxazo le and thiourea derivatives modulating the nlrp3 inflammasome pathway

Publications (2)

Publication Number Publication Date
JP2023531008A JP2023531008A (ja) 2023-07-20
JP2023531008A5 true JP2023531008A5 (cg-RX-API-DMAC7.html) 2024-06-25

Family

ID=76532220

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022578713A Pending JP2023531008A (ja) 2020-06-19 2021-06-18 Nlrp3インフラマソーム経路を調節するジヒドロオキサゾール及びチオ尿素または尿素誘導体

Country Status (12)

Country Link
US (1) US12624010B2 (cg-RX-API-DMAC7.html)
EP (1) EP4168395B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023531008A (cg-RX-API-DMAC7.html)
KR (1) KR20230028425A (cg-RX-API-DMAC7.html)
CN (1) CN115768754B (cg-RX-API-DMAC7.html)
AU (1) AU2021291065B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022025612A2 (cg-RX-API-DMAC7.html)
CA (1) CA3178361A1 (cg-RX-API-DMAC7.html)
IL (1) IL299084A (cg-RX-API-DMAC7.html)
MX (1) MX2022014709A (cg-RX-API-DMAC7.html)
WO (1) WO2021255279A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202212873B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
JP2025502732A (ja) * 2021-12-22 2025-01-28 エーシー・イミューン・エス・アー ジヒドロオキサゾール誘導体化合物
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1270565T3 (da) 1997-01-29 2004-10-04 Pfizer 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater
JP6929792B2 (ja) 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
GB2561540A (en) 2017-03-13 2018-10-24 Nodthera Ltd Chemical compounds
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
CN110914256A (zh) 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
US11370763B2 (en) 2017-07-24 2022-06-28 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
TW201910314A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
AU2018317800A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3668862A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
ES2927851T3 (es) 2017-10-17 2022-11-11 Novartis Ag Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019092172A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CR20200588A (es) * 2018-05-04 2021-06-24 Inflazome Ltd Compuestos novedosos
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
MX2021000660A (es) 2018-07-20 2021-03-25 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1.
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
SG11202101480XA (en) 2018-08-15 2021-03-30 Inflazome Ltd Novel sulfonamideurea compounds
WO2020157069A1 (en) 2019-01-28 2020-08-06 NodThera Limited Amino heterocyclic compounds and uses thereof
JP2022547882A (ja) 2019-09-06 2022-11-16 インフレイゾーム リミテッド Nlrp3阻害剤

Similar Documents

Publication Publication Date Title
JP2022017447A5 (cg-RX-API-DMAC7.html)
JP2021530536A5 (cg-RX-API-DMAC7.html)
CN105121430B (zh) 用于治疗自身免疫性和炎性疾病的类维生素A相关的孤儿受体γ(RORγ)的调节剂
HRP20211225T1 (hr) Sulfoniluree i srodni spojevi i njihova uporaba
TWI758300B (zh) 免疫調節劑化合物
JP2022530985A5 (cg-RX-API-DMAC7.html)
JP7843705B2 (ja) Nlrp3モジュレーターとしてのスルホンイミドアミド化合物
JP2023508142A5 (cg-RX-API-DMAC7.html)
JP2021523200A5 (cg-RX-API-DMAC7.html)
JP2020529405A5 (cg-RX-API-DMAC7.html)
JP2025524640A (ja) Nlrp3インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
CA2777290C (en) Process for the preparation of f-series prostaglandins
EP4482823A1 (en) Di-cyclopropyl based il-17a modulators and uses thereof
CN114981262B (zh) 杂芳基化合物及其制备方法和用途
JP2023532298A (ja) 化合物、組成物及び方法
CN115768754B (zh) 调节nlrp3炎症小体通路的二氢噁唑和硫脲或脲衍生物
HRP20240896T1 (hr) Derivati sulfoniluree i njihova upotreba
WO2019167982A1 (ja) 飽和環縮合ジヒドロピリミジノン又はジヒドロトリアジノン化合物及びその医薬用途
JP2017525684A5 (cg-RX-API-DMAC7.html)
CN110612286A (zh) 氰基取代的稠合双环衍生物及其制备方法和用途
TW202502756A (zh) 作為il17的調節劑的新穎化合物
CN116836176B (zh) 青蒿素类化合物、其制备方法和应用
EP4452972A1 (en) Dihydro-oxazol derivative compounds
JP2026065124A (ja) アミノ酸誘導体の結晶形及びその製造方法
RU2838028C2 (ru) Соединения для лечения pd-l1 заболеваний